{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T08:57:01Z","timestamp":1648889821675},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.remn.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T17:29:32Z","timestamp":1542821372000},"page":"397-406","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET amiloide en enfermedades neurodegenerativas que cursan con demencia"],"prefix":"10.1016","volume":"37","author":[{"given":"V.","family":"Camacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"G\u00f3mez-Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sopena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Garc\u00eda-Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"G\u00f3mez R\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rub\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2018.03.004_bib0205","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nrl.2016.02.016","article-title":"Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaan\u00e1lisis","volume":"32","author":"Niu","year":"2017","journal-title":"Neurologia."},{"key":"10.1016\/j.remn.2018.03.004_bib0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/197140090601900406","article-title":"La lunga attesa: Towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease","volume":"19","author":"Villemagne","year":"2006","journal-title":"Neuroradiol J."},{"key":"10.1016\/j.remn.2018.03.004_bib0215","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer's disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron."},{"key":"10.1016\/j.remn.2018.03.004_bib0220","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1471-4159.2006.03989.x","article-title":"Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics","volume":"97","author":"Masters","year":"2006","journal-title":"J Neurochem."},{"key":"10.1016\/j.remn.2018.03.004_bib0225","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology."},{"key":"10.1016\/j.remn.2018.03.004_bib0230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.remn.2018.03.004_bib0235","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0240","first-page":"303","article-title":"Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus","volume":"34","author":"Arbizu","year":"2015","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remn.2018.03.004_bib0245","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(04)00853-1","article-title":"PET imaging of amyloid in Alzheimer's disease","volume":"3","author":"Nordberg","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0250","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol."},{"issue":"Pt 6","key":"10.1016\/j.remn.2018.03.004_bib0255","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain."},{"key":"10.1016\/j.remn.2018.03.004_bib0260","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.remn.2018.03.004_bib0265","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0270","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","article-title":"Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study","volume":"73","author":"Okello","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.remn.2018.03.004_bib0275","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1212\/WNL.0b013e31823b9c5e","article-title":"Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD","volume":"77","author":"Rabinovici","year":"2011","journal-title":"Neurology."},{"key":"10.1016\/j.remn.2018.03.004_bib0280","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.03.004_bib0285","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.remn.2018.03.004_bib0290","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.115.161927","article-title":"Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: Results from a phase-3 study","volume":"57","author":"Seibyl","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.03.004_bib0295","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-016-0399-z","article-title":"Post-mortem histopathology underlying \u03b2-amyloid PET imaging following flutemetamol F 18 injection","volume":"4","author":"Ikonomovic","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"10.1016\/j.remn.2018.03.004_bib0300","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0305","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-011-2051-2","article-title":"Correlation of early-phase 18F-florbetapir (AV-45\/Amyvid) PET images to FDG images: Preliminary studies","volume":"39","author":"Hsiao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2018.03.004_bib0310","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3233\/JAD-150732","article-title":"Detection of striatal amyloid plaques with [18F]flutemetamol: Validation with postmortem histopathology","volume":"52","author":"Beach","year":"2016","journal-title":"J Alzheimers Dis."},{"key":"10.1016\/j.remn.2018.03.004_bib0315","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2018.03.004_bib0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neurobiolaging.2010.03.011","article-title":"Cognition, glucose metabolism and amyloid burden in Alzheimer's disease","volume":"33","author":"Furst","year":"2012","journal-title":"Neurobiol Aging."},{"key":"10.1016\/j.remn.2018.03.004_bib0325","first-page":"471","article-title":"Early diagnosis of Alzheimer's disease: The prodromal and preclinical phase","volume":"51","author":"Valls-Pedret","year":"2010","journal-title":"Rev Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0330","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/mp.2014.9","article-title":"Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study","volume":"19","author":"Doraiswamy","year":"2014","journal-title":"Mol Psychiatry."},{"key":"10.1016\/j.remn.2018.03.004_bib0335","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA."},{"issue":"Pt 5","key":"10.1016\/j.remn.2018.03.004_bib0340","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain."},{"key":"10.1016\/j.remn.2018.03.004_bib0345","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/brain\/aws125","article-title":"Regional dynamics of amyloid-\u03b2 deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study","volume":"135","author":"Villain","year":"2012","journal-title":"Brain."},{"key":"10.1016\/j.remn.2018.03.004_bib0350","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/cercor\/bhr271","article-title":"CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects","volume":"22","author":"Ewers","year":"2012","journal-title":"Cereb Cortex."},{"key":"10.1016\/j.remn.2018.03.004_bib0355","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum","volume":"67","author":"Ballard","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.remn.2018.03.004_bib0360","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mds.25286","article-title":"\u03b2-amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy","volume":"28","author":"Shimada","year":"2013","journal-title":"Mov Disord."},{"key":"10.1016\/j.remn.2018.03.004_bib0365","first-page":"287","article-title":"Down's syndrome and Alzheimer's dementia: Defining an association","volume":"2","author":"Heston","year":"1984","journal-title":"Psychiatr Dev."},{"key":"10.1016\/j.remn.2018.03.004_bib0370","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jalz.2011.09.229","article-title":"Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B","volume":"8","author":"Handen","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.remn.2018.03.004_bib0375","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1742-1241.2011.02845.x","article-title":"Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment","volume":"66","author":"Zhang","year":"2012","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.remn.2018.03.004_bib0380","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WAD.0b013e31816c92bf","article-title":"Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B","volume":"22","author":"Butters","year":"2008","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"10.1016\/j.remn.2018.03.004_bib0385","doi-asserted-by":"crossref","first-page":"16265","DOI":"10.1523\/JNEUROSCI.2170-12.2012","article-title":"Region-specific hierarchy between atrophy, hypometabolism, and \u03b2-amyloid (A\u03b2) load in Alzheimer's disease dementia","volume":"32","author":"La Joie","year":"2012","journal-title":"J Neurosci."},{"key":"10.1016\/j.remn.2018.03.004_bib0390","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/archneurol.2011.123","article-title":"Longitudinal change of biomarkers in cognitive decline","volume":"68","author":"Lo","year":"2011","journal-title":"Arch Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0395","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archneurol.2009.55","article-title":"Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type","volume":"66","author":"Snider","year":"2009","journal-title":"Arch Neurol."},{"key":"10.1016\/j.remn.2018.03.004_bib0400","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13195-017-0260-z","article-title":"Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database","volume":"9","author":"Ben Bouall\u00e8gue","year":"2017","journal-title":"Alzheimers Res Ther."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X18300489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X18300489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T12:47:24Z","timestamp":1545137244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X18300489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2253654X18300489"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2018.03.004","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET amiloide en enfermedades neurodegenerativas que cursan con demencia","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}